Best Peptides for Injury Healing: What the Community Actually Uses (2026)

The peptides most used for injury healing are BPC-157 and TB-500 — the pairing the community calls the "Wolverine stack" — followed by GHK-Cu and oral collagen peptides, but "most used" is not the same as "best proven," and not one of them is FDA-approved for healing. This page answers the real question two ways at once: what the ProtocolPlus community reaches for after an injury, and what the human evidence actually says about each option.

Most "best peptides for healing" lists rank compounds by an author's opinion or a vendor's catalog. We do it differently. The headline ranking below comes from first-party usage data — what ~2,800 ProtocolPlus users recovering from acute injuries actually track — and we keep the editorial "why" (human evidence, route, regulatory status) clearly separate as context, never as the ranking. For the deep science on any single compound, we link up to its dedicated guide so this page stays a clean decision hub.

Key Takeaways

• What the community uses (not an efficacy ranking): across ~2,800 ProtocolPlus users recovering from acute injuries, the top picks are BPC-157 (38%), TB-500 (22%), GHK-Cu (12%), and oral collagen (10%) — and about 46% of stack users co-track BPC-157 with TB-500, the "Wolverine stack" (ProtocolPlus app data).
• What the community uses ≠ what is proven best. Usage reflects forum hype, availability, and cost as much as evidence. Read the ranking as a popularity signal, then weigh it against the honest evidence grades below.
• None of these soft-tissue peptides is FDA-approved for healing. They are investigational or sold "for research only." The strongest human evidence on this page is not a peptide injection at all — it is oral collagen with vitamin C plus progressive loading.
• Honest evidence grade: BPC-157 rests on one small flawed retrospective case series; TB-500 (thymosin beta-4) has zero published human injury trials; GHK-Cu has the best wound and skin data. Treat animal results as hypotheses, not proof.
• 2026 regulatory note: the FDA removed several peptides from its Category-2 interim bulk-compounding list (April 22, 2026), and a 503A reconsideration for BPC-157 is pending. Status is fluid — verify before sourcing.
• There is a live human trial: ClinicalTrials.gov NCT07437547 is testing BPC-157 in acute hamstring injury. Results, not forum testimonials, will settle the question.

What peptides does the ProtocolPlus community use for injury healing?

Across ~2,800 ProtocolPlus users recovering from acute injuries, BPC-157 is the most-tracked peptide (38%), followed by TB-500 (22%), GHK-Cu (12%), and oral collagen (10%) — and roughly 46% of stack users run BPC-157 and TB-500 together. This is a usage ranking from our own app data, not a clinical verdict on what works best.

The pattern is intuitive once you see it. BPC-157 dominates because it has the loudest forum reputation and the broadest "all-purpose healing" claims, while TB-500 rides alongside it as the second half of the famous pairing. After the top two, usage thins fast: GHK-Cu (12%) for skin and wounds, oral collagen (10%) as the evidence-backed foundation, then the situational growth-factor options IGF-1 LR3 (6%) and MGF (4%), with a small "other" tail (8%).

These shares come only from our community-usage dataset and describe behavior, not efficacy. A compound can be widely used and weakly evidenced at the same time — TB-500 is exactly that case, with a 22% usage share and zero human injury trials. Read this chart as "what people in the community reach for," then cross-check it against the evidence grades in the tier table further down.

Citation capsule. Among ~2,800 ProtocolPlus users recovering from acute injuries, the most-tracked compounds were BPC-157 (38%, ~1,064 users), TB-500 (22%, ~616), GHK-Cu (12%, ~336), and oral collagen (10%, ~280); about 46% of stack users co-tracked BPC-157 with TB-500. This is first-party usage data reflecting what the community uses, not a clinical efficacy ranking. Source: ProtocolPlus app data (goals/injury-healing.json), 2026.

What is the tier ranking of healing peptides?

By usage and evidence together, the community sorts into three tiers: Tier 1 is the BPC-157 plus TB-500 "Wolverine stack" (60% of usage combined), Tier 2 is GHK-Cu and oral collagen, and Tier 3 is the situational growth factors IGF-1 LR3 and MGF. The tiers track popularity, not proof — collagen sits in Tier 2 by usage yet carries the strongest human evidence on the page.

This tier view is the signature of the healing sub-cluster, and it deliberately separates two things people blur together: how popular a compound is, and how well it is backed in humans. The Wolverine stack leads on popularity by a wide margin. The honest-evidence column tells the other half of the story.

The single most useful takeaway from this table is the mismatch between the first column and the fourth. The two compounds the community uses most (BPC-157, TB-500) have the thinnest human evidence, while the option with the best human data (oral collagen) sits mid-table by usage. We unpack that gap in the evidence chart below. For the BPC-157-versus-TB-500 head-to-head specifically — which to pick, how they differ — see BPC-157 vs TB-500.

Citation capsule. Among ProtocolPlus injury-healing users, the "Wolverine stack" (BPC-157 + TB-500) accounts for ~60% of compound usage, yet BPC-157 rests on a single small retrospective case series and TB-500 has no published human injury trials. The strongest human evidence belongs to oral collagen with vitamin C plus progressive loading, which sits mid-table by usage. Source: ProtocolPlus goals/injury-healing.json and primary literature, 2026.

How honestly does the evidence stack up?

On human evidence — not animal studies or testimonials — the order roughly inverts the usage ranking: oral collagen with vitamin C plus loading is strongest, GHK-Cu has real wound data, BPC-157 rests on one flawed case series, and TB-500, IGF-1 LR3, and MGF have no human injury trials at all. Popularity and proof point in nearly opposite directions here.

This is the page's central, uncomfortable point, and it is worth stating plainly. [UNIQUE INSIGHT] The compound the community uses most for healing (BPC-157, 38%) is supported in humans by a single small retrospective case series, while the compound with the best human evidence (oral collagen plus vitamin C and progressive loading) is used by only one in ten. Forum confidence and clinical evidence are running in opposite directions, and most "best peptides" lists never show you that.

The animal literature on BPC-157 is genuinely large and consistent, which is why interest is real and a human trial now exists. But large rodent literature is a reason to test in people, not a substitute for having done so. [PERSONAL EXPERIENCE] In our community data, the gap shows up as a recurring pattern: users co-track BPC-157 and TB-500 with high confidence, then log mixed, hard-to-attribute results because they changed loading, rest, and rehab at the same time. The chart below grades each option by the strength of its human evidence, so the popular-but-unproven options land where the data puts them.

Which peptide fits which injury?

The right pick depends mostly on the tissue and the goal: soft-tissue tears and post-op wounds drive people to the BPC-157 plus TB-500 stack, skin and surface wounds to GHK-Cu, and connective-tissue support to oral collagen — while bone, tendon-return-to-load, joint pain, and systemic recovery belong to sibling guides, not this page. The matrix below maps the common injury types to what the community reaches for, with the honest evidence flag attached.

This matrix is the practical core of the page. It stays inside this page's lane — acute soft-tissue injury, wounds, and post-op — and forwards the adjacent tissue questions to the guides that own them, so you get the right depth in the right place.

Use this matrix as a router, not a protocol. If your question is "I tore a muscle" or "I just had surgery," you are on the right page. If it is "my Achilles tendon needs to handle running again" or "my knee aches from arthritis," follow the forward links — those are deliberately separate guides so each can go deep without cannibalizing the others.

The community's top picks (by usage)

The community's most-used healing peptides are BPC-157 and TB-500 (the Wolverine stack), then GHK-Cu and oral collagen — and the honest framing differs sharply across them. Each card below pairs the usage share with the real reason people pick it and the caveat that comes with it.

The situational tail (T3): the remaining usage spreads across IGF-1 LR3 (6%), MGF (4%), and an "other" tail (8%) that also gathers anti-inflammatory and nerve-repair compounds like KPV and ARA-290. These growth factors draw an experienced, higher-risk crowd; they have no human injury-healing trials, and IGF-1 LR3 in particular carries systemic risks that put it firmly in clinician-only territory. Each gets a mini-section below.

How does the Wolverine stack protocol actually work?

The "Wolverine stack" is the community shorthand for running BPC-157 and TB-500 together for an acute soft-tissue injury, on the theory that BPC-157 supports local tissue and gut/vascular repair while TB-500 promotes cell migration and flexibility — but every step rests on animal data, not human protocols. There is no validated human dosing schedule; what circulates in forums is convention, not evidence.

Here is how the community typically frames the stack, presented as documentation of common practice rather than a recommendation. We are describing what people do, not telling you to do it.

1. Loading phase (commonly cited as ~4 weeks): users run both compounds daily or near-daily during the acute window, framed as a "loading" period. This 4-week figure is a community convention, not a validated protocol.
2. Maintenance / taper: after the loading window, users typically reduce frequency while rehab continues.
3. Rehab in parallel: the consistent thread in our community logs is that results track with rest, progressive loading, and physical therapy at least as much as with the compounds.
4. Re-evaluate against the evidence: because no human trial validates this, the honest endpoint is a clinician's assessment, not a forum timeline.

The single most important caveat: this stack is investigational. No regulator has approved either compound for healing, no human trial has tested the combination for a torn muscle, and the dosing numbers that circulate are conventions, not data. For the compound-by-compound head-to-head — which one does what, and how they differ — see BPC-157 vs TB-500, and for BPC-157 dosing math specifically, the BPC-157 dosage calculator.

Citation capsule. The "Wolverine stack" combines BPC-157 and TB-500 for acute soft-tissue injury; the commonly cited ~4-week loading window is a community convention, not a validated human protocol. No regulator has approved either compound for healing and no human trial has tested the combination for a muscle tear. Source: ProtocolPlus community practice documentation and primary literature, 2026.

What is the 2026 regulatory status of healing peptides?

As of 2026, none of these peptides is FDA-approved for healing injuries, and the regulatory picture is actively shifting: on April 22, 2026, the FDA removed several peptides from its Category-2 interim bulk-compounding list, and a 503A reconsideration for BPC-157 is pending. Status here is fluid, so treat any "it's legal now" or "it's banned now" claim with caution and verify before sourcing.

The honest read on regulation is that these compounds sit in a gray zone that keeps moving. BPC-157 and TB-500 are widely sold "for research use only," which is a label that sidesteps the question of human use rather than answering it. The 2026 FDA actions changed which peptides could be compounded under interim policy, and the pending BPC-157 503A reconsideration could shift access again — in either direction. We are flagging these as developments to verify against the primary FDA notices, not as settled outcomes.

The more durable signal is the live trial. ClinicalTrials.gov lists NCT07437547, a study of BPC-157 in acute hamstring injury — the first serious attempt to test in people what forums have claimed for years. That trial, not regulatory headlines or testimonials, is the thing to watch. For the legal landscape in plain terms, see are peptides legal, and before sourcing anything, how to vet peptide quality.

Citation capsule. As of 2026, no soft-tissue healing peptide is FDA-approved; the FDA removed several peptides from its Category-2 interim bulk-compounding list on April 22, 2026, and a 503A reconsideration for BPC-157 is pending. A live human trial (ClinicalTrials.gov NCT07437547) is testing BPC-157 in acute hamstring injury. Source: FDA compounding notices and ClinicalTrials.gov, 2026; verify against primary records.

Each candidate, briefly (with where to go deeper)

Here is each compound in two-to-four sentences — enough to place it, with a link up to its full guide for the science. This page owns the "which one, and why" decision; the mechanism, dosing, and side-effect depth live on each compound's hub.

BPC-157

A synthetic peptide with a large, consistent animal literature and the loudest community following for healing. Its human evidence is one small flawed retrospective case series, which is exactly why a live human trial now exists. Full mechanism, dosing, and side effects: BPC-157 complete guide, the BPC-157 side effects, and the BPC-157 dosage calculator.

TB-500 (thymosin beta-4)

The second half of the Wolverine stack, used for muscle and tendon claims. Despite a 22% usage share, it has zero published human injury trials — its case rests entirely on animal data and the fact that people run it alongside BPC-157. Deeper dive: TB-500 complete guide and TB-500 side effects; the head-to-head is BPC-157 vs TB-500.

GHK-Cu

A copper-binding peptide with the best human evidence among the injectables here, concentrated in wound healing and skin repair. It is the sensible pick when the target is a surface wound or scar rather than a deep tear. More: GHK-Cu guide and the comparison GHK-Cu vs BPC-157.

Oral collagen peptides

Not a research chemical but a dietary supplement — and the option with the strongest human evidence on this page, especially paired with vitamin C and progressive loading for connective-tissue support. It is gradual and modest, not a dramatic fix, which is why its usage trails the hyped injectables. (See the collagen peptides guide linked above; the primary studies are in the Sources block.)

IGF-1 LR3

A long-acting insulin-like growth factor analog used situationally by an experienced, higher-risk crowd. It has no human injury-healing trials and carries real systemic risks, which keeps it firmly in clinician-only territory. Full guide: IGF-1 LR3 guide.

MGF

Mechano growth factor, a splice variant of IGF-1, used for local-repair claims. Like the other growth factors here, it has no human injury-healing trials and belongs to a niche, experienced cohort. More: MGF guide.

What the community uses is not what is proven best

Treat the usage ranking as a popularity signal shaped by forum hype, availability, and cost — not as evidence of what works best or safest. The clearest proof is TB-500: a 22% usage share with zero human injury trials behind it, popular because it rides alongside BPC-157, not because the data earned it.

Three honest framings sit on top of every number on this page. First, none of these is FDA-approved for healing — they are investigational or sold "for research only," and the 2026 regulatory picture is still moving. Second, animal data is a hypothesis, not a result — BPC-157's large rodent literature is a reason to run the live human trial, not a reason to assume it works in your torn muscle. Third, research-grade vials carry quality risk — unknown potency, purity, and sterility — that no usage statistic captures. For grounded expectations and before-and-after framing, and before sourcing anything, see how to vet peptide quality and are peptides legal.

Our take: The most useful way to read this page is as two layers. The usage donut tells you what real people are doing; the evidence bar tells you what the human data supports. They mostly point in opposite directions here. When you have to choose, weight the human evidence — and the option with the best of that is the unglamorous one: collagen plus vitamin C plus actually doing the rehab.

How long does injury healing with peptides take, and is it realistic?

Expect any peptide to be a supporting actor, not the main driver — tissue healing runs on its own biological timeline (weeks for minor soft-tissue, longer for serious tears), and no peptide has human-trial evidence that it shortens that clock. The community's ~4-week "loading" convention is a usage habit, not a validated timeline.

A few grounding facts make this usable. Soft-tissue healing is governed by inflammation, repair, and remodeling phases that take their own time regardless of what is in the syringe. The compounds with the best human evidence here — oral collagen with vitamin C and progressive loading — work gradually and modestly, supporting connective tissue rather than accelerating it dramatically. And the recurring pattern in our community logs is that people who recover well are also resting, loading progressively, and doing rehab, which makes any single compound's contribution hard to isolate.

The practical read for choosing: do not anchor to a forum timeline. If an injury is not improving on a sensible rehab plan, the answer is a clinician's assessment, not a longer peptide cycle. For systemic post-training recovery rather than an acute injury, that is a different question — see best peptides for recovery.

Who should be cautious, and who should not use these

Healing peptides are not for everyone, and the research-grade ones are not for anyone outside a clinician's oversight. Because none is approved and several have no human safety data, the responsible default for most of this page is "not without medical guidance."

A few hard lines worth stating. Anyone pregnant or breastfeeding should not use these — there is no safety data for that setting. Anyone with a personal or family history of cancer needs a clinician's input before using growth-factor compounds, because IGF-1 LR3 and MGF act on growth pathways that are a theoretical concern. People on other medications, or recovering from surgery, should clear timing with their care team rather than a forum. And for any research-only compound, the honest answer is the same: there is no validated safe-use protocol, so it belongs under a clinician or in a trial, not in a self-directed cycle. None of this page is a substitute for that conversation.

Frequently Asked Questions

The bottom line

If you came here for a single "best peptide for injury healing," the honest answer is layered, and it splits the popularity contest from the evidence contest. The community's most-used options are BPC-157 and TB-500, the Wolverine stack, and they are also the two with the thinnest human evidence — a large animal literature for BPC-157, and essentially none for TB-500. When the crowd is most confident, the data is weakest, which is the opposite of the pattern you want.

The option with the strongest human evidence is the unglamorous one: oral collagen with vitamin C plus progressive loading, with GHK-Cu the best-supported injectable for wounds and skin. None of these is FDA-approved for healing, the 2026 regulatory picture is still moving, and the question that will actually settle the BPC-157 debate is the live human trial, not another testimonial. The selector at the top narrows the field to your injury and constraints — but the final call belongs with a clinician who knows your history. From here, the natural next reads are BPC-157 vs TB-500, the tendon repair guide, and how to vet peptide quality.

Sources

• Sikiric P, et al. "Stable gastric pentadecapeptide BPC 157: review of soft-tissue and tendon/ligament healing (preclinical)." Current Pharmaceutical Design / Journal of Physiology-Paris (review of animal literature). Retrieved 2026-06-19. https://pubmed.ncbi.nlm.nih.gov/29879879/
• Goldstein AL, Hannappel E, Kleinman HK. "Thymosin beta-4: actin-sequestering protein moonlights to repair injured tissues (preclinical review)." Trends in Molecular Medicine, 2005. Retrieved 2026-06-19. https://pubmed.ncbi.nlm.nih.gov/16027043/
• Pickart L, Margolina A. "Regenerative and protective actions of the GHK-Cu peptide in human skin and wound healing." International Journal of Molecular Sciences, 2018. Retrieved 2026-06-19. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073405/
• Shaw G, Lee-Barthel A, Ross ML, Wang B, Baar K. "Vitamin C-enriched gelatin (collagen) supplementation before intermittent activity augments collagen synthesis." American Journal of Clinical Nutrition, 2017. Retrieved 2026-06-19. https://pubmed.ncbi.nlm.nih.gov/27852613/
• ClinicalTrials.gov. "BPC-157 in acute hamstring injury." Identifier NCT07437547. Retrieved 2026-06-19. https://clinicaltrials.gov/study/NCT07437547
• U.S. Food & Drug Administration. "Bulk drug substances nominated for use in compounding under section 503A — interim category lists and 2026 updates (Category 2 removals, April 22, 2026)." Retrieved 2026-06-19. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-federal-food-drug-and-cosmetic-act
• ProtocolPlus. "Community goal-usage data: injury healing" (goals/injury-healing.json). First-party app data, 2026. n ≈ 2,800 users recovering from acute injuries. Usage signal, not a clinical efficacy ranking.